Yasheng Pharmaceutical (06855) Announces 2026 Interim Results: Commercial Hematopoietic Capacity Continues to Improve, Globalization Accelerates

The Zhitong Finance App learned that Yasheng Pharmaceutical (NASDAQ: AAPG; HKEX: 6855) announced its 2026 interim results today. In the first half of 2026, the company achieved total revenue of RMB 302 million, an increase of 29% over the previous year. Driven by the dual engines of two major commercial products, Nellick and Resentol, the company's self-hematopoietic capacity continues to improve. During the reporting period, the company's product sales revenue reached RMB 282 million, an increase of 33% over the previous year.

By the end of the reporting period, the company's total monetary capital was about 1.9 billion yuan, with sufficient capital reserves, providing solid support for global R&D and commercialization expansion.

Currently, the company's core products Nellick and Resentol have a total of 7 globally registered phase III clinical studies being carried out simultaneously. Of these, 4 have been approved by the US FDA and the EU EMA, respectively; Nellick's POLARIS-1 study for newly diagnosed Ph+ ALLPOLARIS-1 patients; a POLARIS-2 study for adult patients treated with CML-CP; GLORA study with risentol combined with BTK inhibitors to treat patients treated with BTK inhibitors; and GLORA-4 studies on the first-line treatment of patients with newly diagnosed high-risk MDS with risentol . It is worth mentioning that risentol is currently the only Bcl-2 inhibitor in the world that is currently promoting registration of phase III clinical trials for medium- and high-risk MDS. Related GLORA-4 research is expected to break the clinical gap that has existed for a long time in the field of medium- and high-risk MDS. Yasheng Pharmaceutical is comprehensively and rapidly advancing these globally registered phase III clinical studies, and global innovation will usher in a period of harvest.

At the same time, in order to accelerate the implementation of the global strategy, the company recently completed a major expansion of the executive team, and the overseas commercialization layout is ready to go. In August 2026, the company appointed Dr. Faiçal Miyara as Chief Business Development Officer (CBO), responsible for the global business development of Yasheng Pharmaceuticals; Jim Ziegler was also appointed as Chief Commercial Officer (CCO), responsible for the commercialization of the company's products in global markets outside of Greater China.

In the future, as the two major commercial products are driven by the dual engines, multiple phase III clinical registrations are progressing rapidly around the world, and the international team and overseas commercialization layout are fully accelerated, and the global innovation value of Yasheng Pharmaceuticals will continue to be realized, which is expected to benefit patients around the world.